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Potential roles of cell-derived microparticles in Multiple Sclerosis 1 
Abstract 2 
Multiple Sclerosis (MS) is a chronic, inflammatory and immune-mediated disease of the 3 
Central Nervous System (CNS). The aetiology of MS remains unclear but probably 4 
represents the interaction between genetic factors, environmental triggers, and an 5 
imbalanced immune system. The term microparticles (also known as microvesicles) 6 
refers to a heterogeneous population of vesicles with a diameter ranging from 0,1 to 1 7 
µm that are released by budding directly from the cell membrane along with 8 
subsequent fission on the membrane stalks and express antigens specific of their 9 
parental cells. Despite being a physiological process, generation of microparticles is 10 
associated with multiple pathologic conditions, including inflammatory and autoimmune 11 
diseases, atherosclerosis and malignancies. Understanding the aspects involved in the 12 
dynamics of microvesicles could then provide new perspectives into MS disease 13 
mechanisms and give rise to new diagnostic tools and therapeutic targets. The present 14 
review summarizes current knowledge about the impact of microparticles in MS 15 
pathophysiology and its diverse potential roles, as well as exploring eventual 16 
improvements in medical treatment. 17 
Introduction 18 
Microparticles (also known as microvesicles) are small bilayer vesicles ranging from 19 
0,1 to 1 µm in diameter which corresponds approximately to 1/7 the diameter of a 20 
human erythrocyte [1]. Along with exosomes and apoptotic blebs, microparticles are 21 
classified as extracellular membrane vesicles (EMV) [2]. Upon certain conditions such 22 
as cell stimulation, stress or activation these vesicles are shaped by budding directly 23 
from the cell membrane along with subsequent fission on the membrane stalks [3]. 24 
Among mammals, microparticles (MPs) are produced by almost all types of cells, 25 
including circulating blood cells (platelets, erythrocytes, neutrophils, lymphocytes and 26 
monocytes/macrophages), vascular cells (endothelial cells, smooth muscle cells and 27 
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fibroblasts) and cells belonging to other tissues or organs in physiological and 28 
pathological conditions (including autoimmune diseases) [4].  29 
The importance of MPs has once been neglected taking into account that they were 30 
considered as cell “dust” or “debris” resulting from cellular processes [5]. However, 31 
according to the latest findings one may suspect important roles in various pathological 32 
states namely autoimmune diseases such as rheumatoid arthritis, systemic lupus 33 
erythematous, Sjögren’s Syndrome [6] and, regarding the Central Nervous System 34 
(CNS), Multiple Sclerosis [7]. It is known that MPs carry cytokines and other molecules 35 
with biological activity, such as immunocomplexes, but also proteins and nucleic acids, 36 
so enhancing the transmission of cellular information including autoimmune responses. 37 
Microvesicles have negatively charged membranes and carry membrane markers from 38 
the parent cell which means it is possible to identify its specific cellular origin [8].  39 
Circulating MPs may be fundamental intervenients in intercellular communication 40 
during inflammation [9]. In fact, they take part in both local and distant cell-to-cell 41 
signalling and promote the exchange of cytoplasmic proteins and large surface 42 
molecules (such as receptors and complement proteins) between cells and therefore 43 
enhancing both direct cell-to-cell and cytokine-mediated communication processes. 44 
Notably, these small vesicles have a greater lifespan and spread more widely than their 45 
parent cells [4]. Understanding the aspects involved in the dynamics of microvesicles 46 
could then provide new perspectives into disease mechanisms and give rise to new 47 
diagnostic tools and therapeutic targets considering the possibility of using them as 48 
new biomarkers for monitoring the disease under study. 49 
Multiple Sclerosis (MS) is a chronic, inflammatory and immune-mediated disease of the 50 
CNS. The aetiology of MS remains unclear but there is evidence it involves the 51 
interaction between genetic factors, environmental triggers and an imbalanced immune 52 
system [10]. It affects more than 2 million people worldwide, with women being more 53 
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susceptible (approximately 3:1) [11]. Disease course and symptoms are highly 54 
heterogeneous and it is characterized by the presence of inflammation, demyelination 55 
and axonal damage upon the brain and the spinal cord. Disease onset usually occurs 56 
in young adults being that the majority of patients (80%) present with a relapsing and 57 
remitting course (RRMS) with the rest having a primary progressive clinical course 58 
(PPMS). The secondary progressive form (SPMS) occurs as a second phase of the 59 
disease for those who initially had RRMS and is characterized by a progressive 60 
worsening of neurologic function [12]. Given its high prevalence, MS is the leading 61 
cause of neurological damage from non-traumatic causes in young adults in the United 62 
States and Europe [13] and thus justifying the importance of its study. 63 
Despite clinical studies concerning MP analyses now have greater numbers than they 64 
used to, comparatively few have specifically addressed neurological conditions. The 65 
present report is therefore, a possible tool for better understanding the nature of MPs 66 
involvement in neurological conditions, namely in Multiple Sclerosis, and to explore the 67 
role of MPs as prognostic markers, biological agents and also potential therapeutic 68 
targets.  69 
Cellular microparticles 70 
Differently from exosome shaping, in which inward membrane invagination occurs, MP 71 
formation requires outward blebbing of the plasma membrane and the latter are also 72 
known as “ectosomes” [14]. Notably, the precise mechanisms leading to vesiculation 73 
remain unclear. However, there are two essential steps during this process: 74 
cytoskeletal reorganization and alterations in phospholipid symmetry. Cell membrane in 75 
its resting state is characterized by the distribution of its phospholipids, with 76 
phosphatidylcholine and sphingomyelin situated on the outer side, and 77 
phosphatidylethanolamine on its internal layer [15]. This asymmetry is guaranteed by 78 
an active transmembrane enzymatic balance related to an equilibrium between 79 
flippase, floppase and scramblase [16].  80 
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When a cell undergoes activation or apoptosis processes there is a sudden release of 81 
intracellular calcium by the endoplasmic reticulum. This immediate rise in cytosolic 82 
calcium leads to the translocation of phosphatidylserine (PS) from the inner leaflet to 83 
the cell surface and activation of cytosolic enzymes such as calpain resulting in the 84 
cleavage of cytoskeleton filaments [17]. As a consequence, membrane-derived MPs 85 
bleb and shed into the extracellular fluid. It is interesting to note that MP membranes 86 
express not only phosphatidylserine but also various phospholipids and oxidized lipids 87 
along with a wide range of proteins specific for cell type from which they originate 88 
making heterogeneity a hallmark of microparticles [18]. In addition, the stimulus 89 
responsible for the induction of vesiculation determines the lipid and protein 90 
composition of MPs. Considering the same cell type receiving different stimuli will result 91 
in microparticles that have distinct components. Furthermore, different cell types 92 
exposed to the same stimulus will produce different microparticles. In fact, there are 93 
plenty of stimuli which might stimulate or inhibit MP formation. Chemical and even 94 
physical stimuli can trigger microparticle liberation, namely cytokines, 95 
immunocomplexes, ultraviolet-B (UVB) light, tobacco smoke extract, unesterified 96 
cholesterol, thrombin, endotoxins and shear stress [4]. Interestingly, it has been 97 
reported that statin treatment and Nitric Oxide (NO) suppress MP production from 98 
endothelial cells. To sum up, all are potentially capable of taking part in the 99 
development of autoimmune diseases or its complications.  100 
In contrast with their formation, much less is known about the mechanisms of MP 101 
elimination. Regarding this process, further investigation is required in order to better 102 
comprehend the mechanisms behind the removal of various membrane vesicle 103 
populations. In regular adults, over 109 cells die each day and each apoptotic cell 104 
liberates several microparticles [19].  As a matter of fact, a correlation between 105 
autoimmune diseases and defects in the clearance of apoptotic cells and their 106 
microvesicles has been found [20],[21].  107 
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Phagocytosis is strongly believed to be the pivotal mechanism responsible for 108 
elimination of MPs with these membrane vesicles being engulfed within phagocytic 109 
cells [22]. Under normal conditions, PS is confined to the internal leaflet of the plasma 110 
membrane but as long as there are apoptotic stimuli to a specific cell, it changes to a 111 
superficial position and is then recognized by phagocytes [23] that apparently express 112 
several molecules responsible for that process, for instance lactadherin, developmental 113 
endothelial locus-1 (DEL-1), alpha (v) integrin/MFG-E8 (milk fat globule epidermal 114 
growth factor), Mer/Gas6, stabilin-2, brain angiogenesis inhibitor 1 (BAI-1) and T-cell 115 
immunoglobulin and mucin domain 4 (TIM-4) that bind PS either directly or through 116 
bridging molecules [24], [25]. Externalization of PS seems to be responsible for the 117 
consequent phagocytosis and internalization of MPs by signalling scavenger receptors 118 
which might induce endocytosis/efferocytosis of MPs.  119 
Aside from PS, opsonisation by IgM may also work as a facilitator mechanism for the 120 
binding and uptake of MPs by macrophages [26]. It is worth to note that glycosylation 121 
patterns might actually work as a means of distinction and prioritization for the 122 
clearance of MPs and other extracellular vesicles by macrophages. On the other hand, 123 
there is a pattern-recognition molecule, complement C1q which has also been related 124 
to microvesicle clearance [27]. Circulating plasma MPs concentration is a result from 125 
the balance between its production and clearance.  126 
Methods 127 
In order to gather information about MPs and its impact in MS, during the initial phase 128 
of this project and before writing the current report, the first step was to perform a 129 
literature review by selecting studies using the electronic database MEDLINE/PubMed  130 
according to specific key words previously determined: “Multiple Sclerosis”, “Multiple 131 
Sclerosis” and “Microparticles” OR “Microparticles” and “Biomarker”. When scanning 132 
the tittle and abstract of studies, some were promptly considered irrelevant for this 133 
review and therefore excluded.  After analysing the reference list from articles found 134 
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with the computerized research additional studies have also been selected. All the 135 
papers included were published in English. Finally, the reading of the identified relevant 136 
articles was conducted. 137 
MPs as active mediators in MS progression 138 
Tight junctions between cerebrovascular endothelial cells are key factors in maintaining 139 
homeostasis and ensuring the integrity of blood-brain barrier (BBB) [28]. Under the 140 
unique environment of the CNS, a paracellular diffusion barrier at the vascular interface 141 
with circulating blood is assembled by these highly specialized complexes, which are 142 
partially regulated by astrocytic foot processes, pericytes, neurons and also 143 
extracellular matrix. Inflammation is strongly correlated with mechanisms of tight 144 
junction deregulation and contribution to loss of barrier function in CNS.  145 
MS is considered to be a chronic inflammatory disease of the CNS, which causes a 146 
heterogeneous range of signs and symptoms due to the fact that a differential 147 
involvement of motor, sensory, visual and autonomic systems is present. It is of note 148 
that amidst the initial and most solid abnormalities of the brain of MS patients are 149 
changes in the BBB and migration of inflammatory cells across the endothelial barrier 150 
[18]. Disrupting the barrier might be a fundamental step in the emergence of 151 
demyelinating lesions. Bearing this in mind, one might say that endothelial barrier 152 
dysfunction is an imprint of MS. This infirmity has a characteristic relapsing clinical 153 
course and its pathology is intimately linked with the perivenular leukocyte infiltration 154 
and demyelination in the CNS.  In fact, MP formation in plasma is a forehand and 155 
lasting outcome of demyelinating events.  156 
The involvement of MPs in several pathological processes appears to be more 157 
complex than initially thought and concerning to MS it has been reported that plasma 158 
MPs induce human endothelial barrier dysfunction and therefore might have an active 159 
function in its progression [2]. The origin of MPs increase is likely related with the 160 
permanent exposure to various inflammatory mediators that markedly display a 161 
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significantly long-term function in the advance of disease.  Additionally, these 162 
mediators may also amplify MPs effect on endothelium and since endothelium is 163 
strongly exposed to MPs, its cells have greater odds of reacting to this MP-mediated 164 
signalling. Signals that damage BBB function are formerly originated from CNS. During 165 
initial stages of MS there is a release of reactive oxygen species (ROS), tumour 166 
necrosis factor (TNF) and interferon gamma (IFN-y) by microglia, which can all induce 167 
MPs formation and liberation. What is more, microvesicles (MVs) from the brain 168 
endothelium have the capability of activating both CD4+ and CD8+ T cells toward 169 
neuronal antigens when lacking any other stimulatory signal and might portray the 170 
inaugural step of brain autoimmunity [29].  171 
To address the relevance of MPs it is necessary to explain the different mechanisms by 172 
which they influence the endothelial barrier function. One of the forms of regulation of 173 
endothelial permeability is correlated with certain surface receptors expressed by MPs 174 
[30]. A commonly used marker for the identification of MPs from endothelial origin 175 
(EMPs), known as platelet and endothelial cell adhesion molecule (PECAM)-1/CD31, is 176 
capable of establishing homotypic interactions and hence modulating endothelial 177 
permeability. On the other hand, EMPs also take part in the regulation of the production 178 
of ROS which induce disruption of the endothelial barrier when augmented. Another 179 
aspect of the repertoire of the influence of MPs in the endothelial barrier consists in the 180 
local release of cytokines and consequent increase in its permeability, thus acting as 181 
pro-inflammatory agents. As an example, it is worth to note that MPs from 182 
microvascular endothelial origin and also from atherosclerotic plaques actually contain 183 
matrix metalloproteinases (MMPs) implicated in the cleavage and shedding of surface 184 
proteins, for instance TNF [30]. As for the ones that derive from monocytes, they 185 
contain inflammatory cytokines that in like manner have the potential to modulate 186 
permeability. As a matter of fact, these same MPs induce the activation of the 187 
transcription factor NF-kB and the expression of adhesion receptors. Finally, MPs also 188 
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constitute vehicles of transportation of RNA and micro(mi)RNA, which can potentially 189 
modulate protein expression in the target cell [17]. It has been demonstrated that some 190 
miRNAs, for example miRNA155, has a negative impact in BBB function during 191 
episodes of neuroinflammation [30]. Taking these facts into consideration, further 192 
studies addressing the analysis and comparison of the distinct components between 193 
healthy and MS microparticles are necessary and could give rise to new targets for 194 
preventing endothelial barrier disruption that occurs concomitantly with the progression 195 
of the disease.  196 
MPs might induce changes in vasculature either by themselves, at higher 197 
concentrations, or by potentiating the outcomes of proinflammatory mediators, such as 198 
Thrombin, when acting synergically at lower concentrations, important for MS onset. 199 
The role of Thrombin in the inflammatory development of experimental MS has been 200 
proven [31]. Indeed, Thrombin is an inflammatory mediator that promotes barrier 201 
contraction and in the long term causes activation of the endothelium due to 202 
inflammation. According to these findings, one may suspect that MPs with no clear 203 
effect on endothelial barriers on their own, might act as sensitizing agents acting on 204 
cells and consequently amplifying the barrier disruption mediated by Thrombin. There 205 
is a link between MS pathophysiology and coagulation that justifies the greater 206 
abundance of certain proteins involved in this cascade, including tissue factor (TF), 207 
responsible for the activation of thrombin, in chronic active plaques. Thrombin is a 208 
cytokine with an unquestionable ability to signal and modify the barrier properties of 209 
endothelial cells, occupying a crossing position between inflammation and coagulation 210 
and thereby perhaps contributing to the progression of several pathologies, including 211 
MS, as revealed by the fact that platelet-MPs (PMPs) might activate leukocytes and 212 
promote their transendothelial migration. Furthermore, MPs have phosphatidylserine as 213 
a component of the outer part of the membrane and so they actually promote a 214 
procoagulant status.  215 
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As stated previously, in MS patients, MPs alone are capable of increasing 216 
extravasation of molecules and cells from the bloodstream in a long term perspective 217 
[30]. Another point is that this effect and even the composition of these vesicles are 218 
different between MS patients and healthy individuals.  219 
MPs as Biomarkers 220 
First of all, it becomes necessary to better perceive the concept of a biomarker as they 221 
correspond to measurable and quantifiable biological features that can then be 222 
appraised as indicators of regular biological processes, pathological processes or 223 
pharmacological responses to medical treatment [16]. Using biomarkers it is possible to 224 
identify pathological conditions and assess the risk of disease, thus definitely being 225 
instruments of great clinical utility. 226 
The hypothesis of resorting to MPs as markers of various pathological processes, 227 
including MS, has been already posed although the potential function of these vesicles 228 
is not fully characterized [32]. A pertinent question is whether MPs are correlated with 229 
the progressive forms of the disease or with any form in particular. Despite being a 230 
recent topic, some studies have been conducted in the sense of seeking to answer 231 
these doubts. 232 
Some MPs may move through a diffusion process due to their small size and thus 233 
make possible their detection in various biological fluids such as blood, urine and even 234 
synovial fluid [17]. Given this possibility, MPs have been highly anticipated as potential 235 
markers of disease states capable of providing clinically relevant information. The 236 
method used for detection consists of a technique called flow cytometry that allows 237 
direct quantification of MPs from biological fluids. Compared to exosomes (50-100nm 238 
in diameter), which are below the detection limit of this approach, MPs are of 239 
considerably larger size (200-1,000 nm) thus justifying the utility of this method in its 240 
quantification. Microglia are immune cells that reside in the CNS and act as agents of 241 
first line defence in cerebral pathologies. Interestingly, every report that studied the 242 
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possible diagnostic value of MPs in CNS diseases has focused not on microglia but 243 
rather on MPs derived from platelets, endothelial cells or oligodendrocytes [33]. 244 
A correlation between MPs and neurological episodes from patients diagnosed with the 245 
RRMS form appears to exist since, during the relapse phase of these patients, a rise in 246 
circulating MPs derived from the endothelial cells has been documented [34]. Not only 247 
these patients show an increase in MPs but in fact all the different forms of MS, 248 
including the progressive ones, are associated with an increase in the amount of 249 
circulating MPs whose origin comes from platelets and endothelial cells [35]. Taking 250 
this assumption into consideration, the variation on levels of circulating MPs leads to 251 
the conclusion that MS, in all its forms, is associated with platelet and endothelial 252 
dysfunction. Interestingly, even patients with typical clinically isolated syndrome (CIS) 253 
and already recovered or in the remission phase show a significant elevation in MPs 254 
when comparing with healthy subjects [30]. Particularly, the fact that the same finding 255 
was also found in CIS patients suggests endothelial dysfunction is present from the 256 
very beginning of proinflammatory demyelinating pathologies which means these 257 
circulating vesicles remain chronically elevated after developing the first neurological 258 
episode. In the same fashion, the vesicles derived from platelets were also found to be 259 
significantly elevated in all MS subtypes which corroborates the hypothesis that 260 
platelets have an essential role in MS [36] [37]. Nevertheless, in CIS patients the 261 
increase in PMPs has not been proven significant and so one might conclude platelet 262 
dysfunction occurs posteriorly to the endothelial dysfunction when the disease is 263 
indeed moving forward. Interestingly, platelet hyperactivity has been linked to patients 264 
with SPMS which even have an increased risk of thromboembolic events due to the 265 
greater levels of platelet aggregation and PMP formation [37]. As a result, we might 266 
look at EMPs and PMPs as good candidates not only for clinical monitoring of disease 267 
state allowing the distinction between CIS and early MS but also for the assessment of 268 
progression of disease and response to therapy.  269 
11 
 
Despite being elevated in all forms of MS and regardless of the phase when 270 
considering RRMS, truth be told, the composition of these vesicles is probably 271 
different.  272 
During the last decade, several studies have shown that extracellular vesicles 273 
(including MPs) harbour many bioactive molecules and exert important regulatory 274 
functions on target cells. In fact, there is a profound relationship between the severity of 275 
various diseases and the molecular content encapsulated in these vesicles, such as 276 
RNA and proteins [38].  277 
Under physiological circumstances the endothelium does not express great levels of 278 
immunoglobulin-like adhesion molecules (IgCAMs). Nonetheless, upon stimulation by 279 
proinflammatory signals or activated T cells there is an upregulation of IgCAMs on the 280 
BBB which might increase penetration of inflammatory cells into the CNS [39]. 281 
Particularly in MS, several soluble markers have been reported as being possibly 282 
detected in plasma or cerebrospinal fluid (CSF). Some examples important to highlight 283 
are PECAM-1 (CD31) and also E-Selectin (CD62E) which are present in MPs from 284 
endothelial origin either while apoptosis is occurring or after inflammatory stimuli. As a 285 
matter of fact, their plasma concentration might reflect the state of endothelial cells or 286 
the presence of endothelial damage. In like manner, another important marker is CD51 287 
(integrin αvβ3) also found in EMPs.  288 
Levels of soluble PECAM-1 are thought to be an index of BBB disruption in MS, as can 289 
be seen by the confirmation of higher levels of CD31+ EMPs during exacerbation but 290 
not remission phase [40]. Having this in mind, PECAM-1 is apparently connected with 291 
clinical relapses along with the presence of gadolinium-enhancing lesions. Brain 292 
magnetic resonance imaging (MRI) has long been settled as the most sensitive in vivo 293 
technique for detecting disease activity and BBB damage [41]. However, it is still an 294 
expensive and time-consuming method and that is why alternative tools are an 295 
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appealing possibility when monitoring disease activity. CD31+ EMP have shown 296 
potential utility in detecting MS as a complementary method used concomitantly with 297 
MRI with gadolinium [42]. This soluble molecule is involved in transendothelial 298 
leukocyte migration characteristic of inflammatory phenomena and is also responsible 299 
for the stimulation of B1 and B2- type integrins on leukocytes that leads to an increase 300 
in their binding to and migration through endothelium. On balance, PECAM-1 seems to 301 
meet the necessary conditions to assert itself as a naturally useful marker of MS 302 
activity. Regarding EMPs measured by CD51, although less pronounced than with 303 
CD31, elevated levels have been detected not only in exacerbation but also during 304 
remission phase [40]. Despite not being exclusive to endothelial cells, CD51 is believed 305 
to reflect erosion of endothelium with consequent exposure of subendothelial matrix 306 
when elevated and differently from CD31, it seems to behave more like a marker of 307 
chronic disease in RRMS, seemingly independent of exacerbation of disease. Yet, the 308 
one or more soluble factors present in MS plasma that cause the release of EMPs 309 
remain unclear and warrant more attention in future investigations. 310 
Therapeutic Perspectives 311 
MPs have proven themselves as a fascinating target for therapeutic intervention in 312 
numerous pathologies. Particularly, management of MS could be significantly improved 313 
by novel therapies based on MPs modulation.  Equally important would be the potential 314 
benefits from the improvement of precocious diagnostic tools that could hasten the 315 
beginning of MS treatments. Indeed, MP profile may foreshadow BBB disruption and 316 
behave as a “surrogate” marker of vascular stress in MS. Currently, MS remains an 317 
incurable condition and existing treatments target the modulation of the immune 318 
system mostly with the use of interferon beta (IFN-β), glatiramer acetate, natalizumab 319 
and fingolimod [34]. In this regard, although there is still much progress to be done, 320 
small but persistent steps are being taken towards the investigation of more efficacious 321 
treatment options. One hypothesis would be trying to prevent disruption of the 322 
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endothelial barrier with the discovery of new targets after clarifying the differences in 323 
composition between MPs from MS patients and healthy subjects. Additionally, a 324 
critical step in the dissection of the various biological effects of MPs will lay in the 325 
development of selective pharmacological agents which modulate either their formation 326 
or, concomitantly or not, their signalling. Some MPs can be harmful and consequently 327 
spread inflammation. MP-focused therapy is based on the hypothesis that, by a 328 
quantitative or qualitative route, there may be a decrease in its pathogenicity and a 329 
possible benefit in the course of the disease. 330 
Fingolimod, the first oral treatment for MS, apparently corrects dysregulated endothelial 331 
MP levels, according to a study that found quantitative and qualitative changes in 332 
circulating MP numbers from MS patients, that way restoring normal values [43]. The 333 
pharmacological control of MPs counts can be viewed as a promising challenge and 334 
innumerable possibilities have been posed, such as statin treatment, fibrates, GPIIbIIIa 335 
antagonists and other anti-platelet treatments. Anything that promotes MPs release can 336 
hypothetically be a target for pharmacological control, including oxidative stress, 337 
cytokines and neurohormonal stimulation by angiotensin II and cathecolamines for 338 
instance. Lastly, we could consider a more embracing approach by trying to modulate 339 
membrane remodelling, and subsequent vesiculation and MPs pouring. In order to 340 
achieve that effect we could possibly target any specific or occasional PS membrane 341 
translocator such as ATP binding cassette subfamily A member 1 (ABCA1) [44]. 342 
Nevertheless, it should be emphasized that, despite huge progress during last decades 343 
has been made, there is still much to know and more detailed studies are necessary to 344 
better understand whether these possible targets for MPs modulation have the 345 
intended effect specifically in MS disease. 346 
Conclusions 347 
In the current report we went through the distinct roles of MPs and exploited its many 348 
potential applications. After reviewing the current available literature, one might 349 
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conclude MPs studies in neurological conditions, including MS, are essential as a 350 
research tool for gaining insights into its pathophysiology and also due to their eventual 351 
clinical benefits in the detection, monitoring and possibly therapeutic intervention in 352 
MS. 353 
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Title page
This should be submitted as a separate file from your manuscript (to ensure anonymity in the 
peer review process) and should include:  
• Article title.
• Authors’ names, titles (e.g. MD, PhD, MSc, etc.) and institutional affiliations.
• Corresponding author: name, mailing address, telephone and fax numbers, email address.
• Keywords (maximum of 10), according to MeSH terms, whenever possible.
• A short title (running head) (up to 70 characters).
• Abstract word count (up to 250 words).
• Disclosure of conflicts of interest. Any conflict of interests should be declared. If authors 
have no declaration it should be written: “The authors declare no conflict of interest”.
Manuscript body:
The Manuscript body must be anonymous, not containing the names or affiliations 
of the authors. It must be structured in the following order: title, abstract, body text, 
acknowledgements, references, tables, and figures captions/legends. The manuscript body should 
contain the title and the abstract, since the title page is not sent to reviewers during peer-review.
• The text must be formatted as follow:
• Arial fonts, size: 11 points.
• Double line spacing (see paragraph menu). 
• Aligned to the left (not justified). 
Showing continuous line numbers on the left border of the page. For MS Word you can add 
line numbers by going to: Page Layout -> Line Numbers -> select “Continuous”; for OpenOffice:  
Tools -> Line Numbering -> tick “Show numbering”.
Title  
A descriptive and scientifically accurate article title should be provided.
Abstract (250 words maximum)
An abstract should be prepared for all types of manuscript, except Editorials.
Abstracts of Original Research articles should be structured as: background/objective, 
methods, results, and conclusions. If the publication is associated with a registered clinical trial, 
the trial registration number should be referred at the end of the abstract. 
Case-reports should be structured as background/introduction, case report, discussion. 
Systematic review articles should have a structured abstract with generally the same headings 
as Original Research articles, whereas narrative review articles can have a structured or 
unstructured abstract, as deemed appropriate by the authors.
Abstracts for Viewpoint articles and Letters to the Editor, can have a structured or 
unstructured abstracts, as deemed appropriate by the authors.
Body text
Original research articles
Original research articles should be structured as follows:
Introduction: Should present the background for the investigation and justify its relevancy. 
Claims should be supported by appropriate references. Introduction should end by stating 
the objectives of the study.
Methods: Should allow the reproduction of results and therefore must provide enough 
detail. Appropriate subheadings can be included, if needed.
Results: Should include detailed descriptions of generated data. This section can be 
separated into subsections with concise self-explanatory subheadings.
Discussion: Should be brief but comprehensive and well argued, summarise and discuss 
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the main findings, their clinical relevance, the strengths and limitations of the study, future 
perspectives with suggestion of experiments to be addressed in the future.
Review articles and Drug Reviews
These types of articles should be organised in sections and subsections, as deemed appropriate 
by the authors
Case Reports and Case Snippets
These types of articles should be organised in the general following sections: Introduction/
Background, Case Report, Discussion. Subsections should be used as deemed appropriate by the 
authors
Acknowledgements
This section should name everyone who has contributed to the work but does not qualify as 
an author. People mentioned in this section must be informed and only upon consent should 
their names be included along with their contributions. Financial support (with grant number, if 
applicable) should also be stated here.
References
References citation in the text should be numbered sequentially along the text, within square 
brackets. The use of a reference management tool (such as Endnote or Reference Manager) is 
recommended. References must be formatted in Vancouver style. 
Only published or accepted for publication material can be referenced. Personal 
communications can be included in the text but not in the references list. 
Tables
Tables should be smaller than a page, without picture elements or text boxes. Tables should 
have a concise but descriptive title and should be numbered in Arabic numerals. Table footnotes 
should explain any abbreviations or symbols that should be indicated by superscript lower-case 
letters on the body table.
Figures
Figures should have a concise but descriptive title and should be numbered in Arabic 
numerals. If the article is accepted for publication, the authors may be asked to submit higher 
resolution figures. Copyright pictures shall not be published unless the authors submit a written 
consent from the copyright holder to allow publishing.
Figures should be tested and printed on a personal printer prior to submission. The printed 
image, resized to the intended dimensions, is almost a replication of how the picture will look 
online. It shall be clearly perceived, non-pixelated nor grainy. Only flattened versions of layered 
images are allowed. Each figure can only have a 2-point white space border, thus cropping is 
strongly advised. For text within figures, Arial fonts between 8 to 11 points should be used and 
must be readable. When symbols are used, the font information should be embedded.
Photographs should be submitted as *.eps at high-resolution (300 dpi or more), *.tif or *.pdf. 
Graphics should be submitted in *.eps or *.pdf format, to allow proper reproduction. MS Office 
graphics are also acceptable, if submitted in their original, editable formats.
Lines, rules and strokes should be between 0.5-1.5 points for reproducibility purposes.
Nomenclature
All units should be in International System (SI). Drugs should be designated by their 
International Non-Proprietary Name (INN).
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3.3. Supporting Information
Code of Experimental Practice and Ethics
The minimal ethics requirements are those recommended by the Code of Ethics of the World 
Medical Association (Declaration of Helsinki). Authors should provide information regarding 
ethics on patient informed consent, data privacy as well as competing interests. If the authors have 
submitted a related manuscript elsewhere, they should disclose this information prior to submission. 
3.4. Submission Checklist
Please ensure you have addressed the following issues prior submission:
• Details for competing interests.
•  Details for financial disclosure.
•  Details for authors contribution.
•  Participants informed consent statement.
•  Authorisation for use of figures included in the manuscript, not produced by the authors 
and subject to copyright.
•  Authorship, affiliations and email addresses are correct.
•  Cover letter addressed to the Editor-in-Chief.
•  Identification of potential reviewers and their email addresses (to be introduced at the 
online submission platform).
•  Manuscript, figure and tables comply with the author guidelines, including the correct 
format, SI units and standard nomenclature.
•  Separated files for Title page (*.doc+*.pdf) and Manuscript body (*.doc+*.pdf)—4 in total.
•  Manuscript body does not contain the names or affiliations of the authors, or other direct-
ly identifying information, and contain the title and the abstract.
If you have any questions, please contact the editorial office at ijcnmh@arc-publishing.org
4. Overview of the Editorial Process
The International Journal of Clinical Neurosciences and Mental Health aims to provide an 
efficient and constructive view of the manuscripts submitted to achieve a high quality level of 
publications. The editorial board is constituted by expert leaders in several areas of medicine 
particularly in Clinical Neuroscience and Mental Health.  
Once submitted, the manuscript is assigned to an editor which evaluates and decides whether 
the manuscript is accepted for peer-review. At this initial phase, the editor evaluates if the 
manuscript fulfils the scope of the journal according to the content and minimum quality 
standards.  For peer-review, one or two additional expert field editors will comment on the 
manuscript and decide on whether it is accepted for publishing with minor corrections or not 
accepted for publishing. The editor may ask authors to resubmit after revision (minor or major). 
Decision is based on technical and scientific merits of the work. Reviewers can be asked to be 
disclosed or stay anonymous. Authors can exclude specific editors or reviewers from the process, 
upon submission, a rational should be provided.
Upon evaluation, an email is sent to the corresponding author with the decision. If accepted, 
the manuscript enters the production process. It takes approximately 2-4 weeks for the 
manuscript to be published.
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4.1. Appeal Process
The editors will respond to appeals from authors which manuscripts were rejected. Their 
interests should be sent to the Editor. 
Two directions can be followed: 
• If the Editor does not accept the appeal, further right to appeal is denied.
• If the Editor accepts the appeal, a further review will be asked. After the new review, the 
editor can reject or accept the appeal. If rejected, nothing else can be done, if accepted the 
author is able to resubmit the manuscript.
The reasons for not accepting a manuscript for consideration can be:
•  The manuscript does not follow the scope of the journal.
•  The manuscript has potential interest but there are methodological concerns after peer-re-
view or editorial examination.
